Cerity Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Cerity Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,436	Closed	-$42.8K	–	2523
2024 Q3	$42.8K	Buy	+3,436	New	+$42.7K	﹤0.01%	2493

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Cerity Partners's KPTI Position: Q4 2024 in Review

Cerity Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 3,436 shares — an estimated $42.8K sold.

Cerity Partners first reported a position in KPTI in Q3 2024 and held it in 1 quarter. The position peaked at $42.8K in Q3 2024. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

Cerity Partners reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
Cerity Partners sold 3,436 Karyopharm Therapeutics shares in Q4 2024, an estimated $42.8K.
Cerity Partners first reported a position in Karyopharm Therapeutics in Q3 2024 and held it in 1 quarter.
Cerity Partners's Karyopharm Therapeutics position peaked at $42.8K in Q3 2024.
87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Cerity Partners's 13F filing for Q4 2024, filed 13 Feb 2025.